ClinicalTrials.gg
Enrolling by invitationNCT07460063Updated Nov 16, 2026

Routine vs. Early Postpartum Depression Screening: A Pragmatic Clinical Trial

An interventional study of Early PPD Screening in Postpartum Depression (PPD), sponsored by Massachusetts General Hospital. Enrolling by invitation at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Screening

How we know

Updated Nov 12, 2026Now Enrolling by invitationFirst site in United States+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
428
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 220 studies in Depression, Postpartum with a site in United States — 38 open to participants now, 49 under way, 3 of them phase 3. Depression, Postpartum · United States.

Planned enrollment
25th of 198
428 · median 86
Started
2026
with 13 others
No phase
152 of 220
32 open now
Primary completion
2027-09
later than 30 of 48 live
Registered
209th of 220
by date
Lead sponsor
6 of 220
Massachusetts General Hospital

Among the 220 studies in Depression, Postpartum with a site in United States, this one is the 25th largest by planned enrollment of the 198 interventional ones that give a count, is one of 14 that started in 2026, is one of 152 with no phase, reaches primary completion later than 30 of the 48 other live ones, and was the 209th registered.

Depression, Postpartum

570 studies on the registry are indexed under Depression, Postpartum; 135 are open to participants now.

Browse Depression, Postpartum studies →

Open to participants now

38 of the 220 studies in Depression, Postpartum with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Depression, Postpartum studies recruiting now, 54 (61%) set no upper age limit and 31 (35%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 220 studies in Depression, Postpartum with a site in United States, or all of them as a file.
02

Study summary

After having a baby, some women develop a condition called postpartum depression, or PPD, which can cause sadness, anxiety, and difficulty bonding with their newborn. Right now, most women aren't screened for PPD until about 6 to 8 weeks after giving birth, but this study wants to find out if checking earlier could help identify signs sooner. To test this, researchers will work with 428 women who deliver at an MGH hospital clinic and have no history of depression. Each woman will be randomly placed into one of two groups: one group will fill out a short depression questionnaire online at 2 to 3 weeks after delivery, while the other group will follow the usual process and complete the same questionnaire at their regular 6-week visit. The results will go to each woman's doctor, who will decide if any follow-up care is needed, just like they normally would. The study will follow each participant for 6 months after delivery to see whether earlier screening makes a difference.

Read the detailed description

This is a pragmatic clinical trial comparing early EPDS screening (2 weeks postpartum) with standard care (6 weeks postpartum) in 428 patients without a history of depression and delivering and receiving obstetric care at an MGH-affiliated clinic. Patients will be stratified as high-risk or low-risk for PPD using a validated prediction model and then randomized (1:1) to one of two arms: early screening (intervention group) or routine care (control group). Patients and clinical team members will be blinded to risk assignment. The early EPDS screening group will be sent an electronic EPDS (PROMS) at 2-3 weeks postpartum by the MGH Obstetric Clinic Staff; results will be directed to the patient's primary obstetric provider, mirroring the clinical process for the routine 6-week postpartum EPDS screen. The routine care group will continue to receive standard postpartum care, which includes a visit around 6 to 8 weeks postpartum and administration of the EPDS survey. Clinic staff will review and manage screening results according to local clinic protocols (e.g., arranging virtual or in-person visits, social work referrals, etc.); this includes managing reports of self-harm, which is a component of the scale. The research team will not be responsible for sending or reviewing EPDS results in real-time. The study will be conducted until 214 high- and 214 low-risk patients have been randomized and followed through 6 months postpartum.

This study is a pilot project designed to generate preliminary data for a larger definitive trial. In the retrospective data, 10.1% of patients in the high-risk group and 2.0% of patients in the low-risk group had an EPDS score>12 at 6 weeks postpartum (non-responders were considered not to have a positive screen). Assuming the same rates in this prospective cohort, 107 individuals in each risk grouping would provide 80% power at alpha=0.05 to detect the same effect (one-sided Z-test). The study will enroll 107 individuals in the control arm in each risk grouping.

The study will employ an intent-to-treat approach, analyzing all randomized participants in their assigned groups, with a secondary per-protocol analysis limited to participants who completed their assigned screening protocol.

The primary endpoint, EPDS-positive screen (EPDS >12 vs ≤12), will be compared using chi-square tests within the standard screening group between the high- and low-risk groups. EPDS score at 2 weeks postpartum in the early screening group will be compared between high-risk and low-risk participants using Mann-Whitney U tests for median scores or t-tests for mean scores, if normally distributed. Secondary EPDS score endpoints at 6 weeks postpartum will be analyzed using the same methods. The binary endpoints of PPD incidence and mental health referral/treatment at 6 months (defined as the presence of a mood/depressive disorder diagnosis code, psychiatric medication prescription, or EPDS >12) will be compared between groups using chi-square tests. Feasibility endpoints, including EPDS completion rates at 2 and 6 weeks and positive screen rates (EPDS >10 and >12), will be analyzed using chi-square tests. Time to mental health referral or treatment initiation will be evaluated using Kaplan-Meier survival curves with log-rank tests for between-group comparisons. Model validation will be assessed through AUROC analysis for discrimination between those who develop PPD and those who do not, along with calibration plots comparing predicted versus observed PPD rates.

Using an intention-to-treat analytic plan, the primary analysis will compare rates of positive EPDS screening among the high- and low-risk groups in the control arm; non-responders to the EPDS screen will be considered "screen negative" to mirror the approach used for our sample size calculation. For other analyses, a complete-case approach will be used as the primary comparison method.

Regression will adjust for patient characteristics, such as race (White vs. non-White), language (English vs. non-English), age (\< vs ≥35 years), and mode of delivery (vaginal vs. cesarean delivery), to examine effect modification across various subgroups.

03

Conditions studied

  • Postpartum Depression (PPD)

Keywords

  • postpartum
  • depression
  • depression screening
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Live birth, term (≥37 weeks) delivery at Massachusetts General Hospital
  2. Access to Patient Gateway, as to receive the electronic EPDS scale
  3. Primary obstetric provider at MGH or its affiliated clinics
  4. No recent history of depressive disorder as determined through diagnoses or medication use*
  5. Age ≥18 years old

Exclusion criteria

Exclusion Criteria:

  1. A diagnosis code in the EHR for major depressive disorder, bipolar disorder, or psychotic disorder within the year prior to delivery
  2. Antidepressant, antipsychotic, or bipolar medication use within the year prior to delivery
  3. Age \<18 years old
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
428 participants (estimated)

Study arms

  • Experimental
    Early Screening among High-Risk Participants

    Early PPD screening among individuals identified at high risk for PPD

    Behavioral: Early PPD Screening

  • No intervention
    Routine Care among High-Risk Participants

    Routine care among individuals identified at high risk for PPD

  • Experimental
    Early Screening among Low-Risk Participants

    arly PPD screening among individuals identified at low risk for PPD

    Behavioral: Early PPD Screening

  • No intervention
    Routine Care among Low-Risk Participants

    Routine care among individuals identified at low risk for PPD

Interventions

  • BehavioralEarly PPD Screening

    Edinburgh Perinatal Depression Scale (EPDS) administered at approximately 2 weeks postpartum

06

What researchers measure

Primary outcomes

  1. Proportion of positive Edinburgh Postnatal Depression Scale (EPDS) screens at 6 weeks in the routine care group by postpartum depression (PPD) risk status

    To compare rates of positive EPDS screens (EPDS \>12) at 6 weeks (in the routine care group) by PPD risk status (high vs. low)

    Time frame: 6 weeks postpartum is defined as a period between 28-56 days after the day of delivery

  2. Edinburgh Peripartum Depression Scale (EPDS) scores at 2 weeks postpartum in the early screening group by PPD risk status

    To compare EPDS scores at 2 weeks postpartum by PPD risk status (high vs. low) in the early screening group. EPDS score: range 0-30; higher scores are more strongly associated with PPD

    Time frame: 2 weeks postpartum is defined as a period between 8-24 days after the day of delivery

Secondary outcomes

  1. Edinburgh Postnatal Depression Scale (EPDS) score at 6 weeks in the routine screening group by PPD risk status (high vs. low).

    To compare EPDS scores at 6 weeks postpartum among women at high and low risk in the standard screening group. EPDS score: range 0-30; higher scores are more strongly associated with PPD

    Time frame: 6 weeks postpartum is defined as a period between 28-56 days after the day of delivery

  2. Proportion of individuals with PPD at 6 months postpartum in the routine care group by PPD risk status

    To compare the incidence of PPD (as defined by the presence of a diagnosis code for a mood or depressive disorder, a psychiatric medication prescription, or EPDS results \>12) at 6 months postpartum by PPD risk status (high vs. low) in the routine care group

    Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery

  3. Proportion of individuals with PPD at 6 months postpartum in the early screening group by PPD risk status

    To compare the incidence of PPD (as defined by the presence of a diagnosis code for a mood or depressive disorder, a psychiatric medication prescription, or EPDS results \>12) at 6 months postpartum by PPD risk status (high vs. low) in the early screening group

    Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery

  4. Proportion of individuals with PPD (excluding EPDS diagnositic criteria) at 6 months postpartum in the routine care group by PPD risk status

    To compare the incidence of PPD (as defined by the presence of a diagnosis code for a mood or depressive disorder, or a psychiatric medication prescription, but not an EPDS results \>12) at 6 months postpartum by PPD risk status (high vs. low) in the routine care group

    Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery

  5. Proportion of individuals with PPD (excluding EPDS diagnostic criteria) at 6 months postpartum in the early screening group by PPD risk status

    To compare the incidence of PPD (as defined by the presence of a diagnosis code for a mood or depressive disorder, or a psychiatric medication prescription, but not an EPDS results \>12) at 6 months postpartum by PPD risk status (high vs. low) in the early screening group

    Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery

  6. Edinburgh Postnatal Depression Scale (EPDS) completion rates at 2 weeks postpartum in the early screening group by PPD risk status

    To evaluate the feasibility of electronic-based EPDS screening at 2 weeks postpartum in the early screening group, as measured by screening completion rates

    Time frame: 2 weeks postpartum is defined as a period between 8-24 days after the day of delivery

  7. Edinburgh Postnatal Depression Scale (EPDS) completion rates at 6 weeks postpartum in the routine care group by PPD risk status

    To examine EPDS completion rates at 6 weeks by PPD risk status (high vs. low) in the routine care group

    Time frame: 6 weeks postpartum is defined as a period between 28-56 days after the day of delivery

  8. Proportion of positive Edinburgh Postnatal Depression Scale (EPDS) screens at 2 weeks in the early screening group by PPD risk status

    To compare rates of positive EPDS screens (EPDS \>10 and \>12) at 2 weeks (early screening group) by PPD risk status (high vs. low)

    Time frame: 2 weeks postpartum is defined as a period between 8-24 days after the day of delivery

  9. Proportion of positive Edinburgh Postnatal Depression Scale (EPDS) screens at 6 weeks in the early screening group by PPD risk status

    To compare rates of positive EPDS screens (EPDS \>10 and \>12) at 6 weeks postpartum (early screening group) by PPD risk status (high vs. low)

    Time frame: 6 weeks postpartum is defined as a period between 28-56 days after the day of delivery

  10. Proportion of participants with mental health referrals (social work, therapy, psychology, psychiatry) and treatment (psychotherapy, medication prescription) within 6 months postpartum in the routine care group by PPD risk status

    To compare mental health referrals and treatment within 6 months postpartum by PPD risk status (high vs. low) in the routine care group

    Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery

  11. Proportion of participants with mental health referrals (social work, therapy, psychology, psychiatry) and treatment (psychotherapy, medication prescription) within 6 months postpartum in the early screening group by PPD risk status

    To compare mental health referrals and treatment within 6 months postpartum by PPD risk status (high vs. low) in the early screening group

    Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery

  12. Days between delivery and first diagnosis of a postpartum mood disorder within 6 months postpartum by PPD risk status

    To compare days between delivery and first diagnosis of a postpartum mood disorder (based on diagnosis code and/or documentation with a clinical note) within 6 months postpartum by PPD risk status (high vs. low)

    Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery

  13. Days between delivery and first mental health referral or treatment within 6 months postpartum in the routine care group by PPD risk status

    To compare time to mental health referral and treatment within 6 months postpartum by PPD risk status (high vs. low) in the routine care group

    Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery

  14. Days between delivery and first mental health referral or treatment within 6 months postpartum in the early screening group by PPD risk status

    To compare time to mental health referral and treatment within 6 months postpartum by PPD risk status (high vs. low) in the early screening group

    Time frame: 6 months postpartum is defined as a period between the day of delivery and 180 days after delivery

  15. Change in Edinburgh Postnatal Depression Scale (EPDS) score between 2 and 6 weeks postpartum in the early screening group by PPD risk status

    To compare the change in EPDS score between 2 and 6 weeks postpartum by PPD risk status (high vs. low) in the early screening group. EPDS score: range 0-30; higher scores are more strongly associated with PPD.

    Time frame: 2 weeks postpartum is defined as a period between 8-24 days after the day of delivery; 6 weeks postpartum is defined as a period between 28-56 days after the day of delivery

07

Study locations

1 site
08

References and documents

Publications

  • Clapp MA, Castro VM, Verhaak P, McCoy TH, Shook LL, Edlow AG, Perlis RH. Stratifying Risk for Postpartum Depression at Time of Hospital Discharge. Am J Psychiatry. 2025 Jun 1;182(6):551-559. doi: 10.1176/appi.ajp.20240381. Epub 2025 May 19. PubMed 40384019 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Sep 2027, 10 months after the start.

Of 259 non-industry interventional studies with no phase under Depression, Postpartum, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 10 months is below that.

Counting every sponsor, half of 265 studies reached it within 23 months; a quarter within 11 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Sep 2026 → Nov 2026, primary completion Aug 2027 → Sep 2027 and completion Jan 2028 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 10, 2026
StartActual
Nov 13, 2026was Sep 2026
Primary completionEst.
Sep 2027was Aug 2027
CompletionEst.
Feb 2028was Jan 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 12, 2026
Sites
1 site added — first site in United States
Show site
  • Massachusetts General Hospital · Boston, United States
Nov 12, 2026
Start date
Sep 2026→Nov 2026
Nov 12, 2026
Primary completion
Aug 2027→Sep 2027
Nov 12, 2026
Study completion
Jan 2028→Feb 2028
Nov 12, 2026
Contact
No study contact listed any more: removed m•••@mgh.harvard.edu · •••2000
Nov 12, 2026
Show all 2 updates
  1. Nov 16, 2026
    Minor edits only
    + 1 other change: date precision
  2. Nov 12, 2026
    Not yet recruiting→Enrolling by invitation
    1 site added — first site in United States
    Show site
    • Massachusetts General Hospital · Boston, United States
    Start date Sep 2026→Nov 2026
    Primary completion Aug 2027→Sep 2027
    Study completion Jan 2028→Feb 2028
    Contact No study contact listed any more: removed m•••@mgh.harvard.edu · •••2000
    + 4 other changes: verification date, oversight details, references and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07460063
Responsible party
Mark Clapp, MD MPH (Clinical Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Mar 10, 2026
Start date
Nov 13, 2026
Primary completion
Sep 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Roy H Perlis, MD, MSc
principal investigator · Massachusetts General Hospital
Mark A Clapp, MD, MPH
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion